Loading...
•
Mar 31, 2022
Dyne Therapeutics Q1 2022 Earnings Report
Reported financial results for the first quarter of 2022 and business highlights.
Key Takeaways
Dyne Therapeutics reported a net loss of $35.6 million for the first quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $323.2 million as of March 31, 2022.
Initiation of patient dosing in multiple ascending dose clinical trials for DYNE-251 in DMD and DYNE-101 in DM1 anticipated in mid-2022.
Response to FDA relating to IND for DYNE-251 in DMD is expected to be submitted in the second quarter.
Regulatory filings in multiple countries for DYNE-101 in DM1 are expected to be submitted in the second quarter.
Cash, cash equivalents and marketable securities were $323.2 million as of March 31, 2022, which is anticipated to fund operations into the second half of 2024.
Dyne Therapeutics
Dyne Therapeutics
Forward Guidance
Dyne expects to submit an IND for DYNE-301 in FSHD in the second half of 2022 and anticipates initiating patient dosing in global multiple ascending dose (MAD) clinical trials for DYNE-251 in DMD and DYNE-101 in DM1 in mid-2022.
Positive Outlook
- Submitting response to the FDA’s clinical hold letter for DYNE-251 in DMD in Q2 2022
- Submitting regulatory filings in multiple countries for DYNE-101 in DM1 in Q2 2022
- Initiating patient dosing in global multiple ascending dose (MAD) clinical trials for DYNE-251 in DMD in mid-2022
- Initiating patient dosing in global multiple ascending dose (MAD) clinical trials for DYNE-101 in DM1 in mid-2022
- Submitting an IND for DYNE-301 in FSHD in the second half of 2022